Which is better, Semax or Selank?
Selank has the higher grade (human RCT versus human observational) because two of its trials were randomized, but both were unblinded, compared it with or added it to a benzodiazepine with no placebo group, come from the developer's network, and have not been independently replicated, so the grade does not show that selank works better than semax. Neither has an indexed double blind placebo controlled trial, and both rely on studies from the developing Russian research groups. Semax has a regulatory edge: it is covered by HHS's draft enforcement discretion policy (FDA's drug center recommended against listing; the advisory committee voted in favor, per HHS's Appendix B), while selank was not reviewed and is not covered. The draft is not binding and does not change either evidence grade. They were also studied for different things, so the choice depends on the goal. If the goal is anxiety specifically, selank is the one studied for it, but approved anxiety treatments with real trials should come first. [1] [2] [3] [4] [5] [10] [13]
How do Semax and Selank compare?
| Dimension | Semax | Selank |
|---|---|---|
| What it is [6] [7] | Heptapeptide analog of ACTH fragment 4-10 (Met-Glu-His-Phe-Pro-Gly-Pro); does not stimulate cortisol release. | Heptapeptide analog of tuftsin (Thr-Lys-Pro-Arg), an immune peptide fragment of IgG, extended with Pro-Gly-Pro. |
| Note: Both use the same Pro-Gly-Pro tail for stability. | ||
| Main use studied [1] [2] [8] | Acute ischemic stroke recovery and chronic cerebrovascular insufficiency; cognitive and asthenic uses in Russian labeling. | Generalized anxiety disorder and neurasthenia. |
| Proposed mechanism [6] [7] | Raised hippocampal BDNF protein about 1.4 fold and trkB expression within hours of one intranasal dose in rats; monoamine and anti-ischemic effects in rodents. | Allosteric GABA-A modulation, inhibition of enkephalin degrading enzymes, and monoamine and BDNF effects in rodent and cell work. |
| Human evidence [1] [2] [3] [8] [9] [10] | Open comparative Russian stroke studies (1997, 2005, 2018) reporting faster neurological recovery and fewer exacerbations; no blinding or placebo. | Small Russian anxiety trials (2008, 2014, 2015), two of them randomized: anxiety relief similar to the benzodiazepine medazepam, and earlier relief with fewer benzodiazepine side effects when selank was added to phenazepam. All unblinded, with no placebo group and no independent replication. |
| Doses in the literature [1] [2] | Intranasal 12 to 18 mg per day (1% solution) for 5 to 10 days in acute stroke; roughly 0.2 to 2 mg per day (0.1% solution) for cognitive uses. | Intranasal 0.15% solution at roughly 0.3 to 2.7 mg per day for 10 to 14 days. |
| Reported side effects [1] [3] | Nasal irritation; anxiety, irritability, or insomnia reported anecdotally at higher doses. | Nasal irritation; fatigue or drowsiness reported anecdotally; less sedation than phenazepam in the comparative study. |
| FDA and compounding status [4] [5] [13] [14] | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (intranasal only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). | Nomination withdrawn, so it is in no 503A category, not on the bulks list, not reviewed by PCAC in July 2026, and not covered by HHS's October 2026 draft policy; a 503A pharmacy has no federal basis to compound it from bulk. |
| Typical cost [4] [5] [12] [13] | No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price. | No lawful compounded price: selank is not on the 503A bulks list, was not reviewed by PCAC in July 2026, and is not covered by HHS's draft policy. |
| Note: Research chemical nasal sprays and vials sold for human use are unapproved drugs. | ||
| WADA status [11] | Not named on the WADA Prohibited List; whether it falls under S0 (non-approved substances) is unclear, so tested athletes should confirm with their anti-doping organization. | Not named on the WADA Prohibited List; whether it falls under S0 (non-approved substances) is unclear, so tested athletes should confirm with their anti-doping organization. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Semax | Selank |
|---|---|---|
| Class | Synthetic heptapeptide analog of ACTH fragment 4-10 (Met-Glu-His-Phe-Pro-Gly-Pro), a melanocortin derived nootropic and neuroprotective peptide | Synthetic heptapeptide analog of the immune tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended with Pro-Gly-Pro, a Russian anxiolytic peptide |
| What it is | Nasal peptide registered in Russia; rodent and Russian stroke trial data; not FDA approved; nasal use in HHS's October 2026 draft policy. | Anti-anxiety nasal peptide registered in Russia, with small randomized but unblinded trials against benzodiazepines; not FDA approved, nomination withdrawn. |
| Evidence | Evidence: Human observational evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: HHS interim policy (draft) | Regulatory: Nomination withdrawn |
| Compounding | Semax is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds semax when every condition is met: a single active ingredient only (no blends or stacks), the allowed route (intranasal only), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add semax to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs. | Selank was placed on the FDA 503A Category 2 list (substances with significant safety risks) in 2023. The FDA Category 2 page current as of April 22, 2026 now lists selank acetate under bulk drug substances nominated but withdrawn, so it is no longer in Category 2, but it is not on the 503A bulks list and was not among the peptides FDA presented to the Pharmacy Compounding Advisory Committee on July 23 to 24, 2026. With no active nomination and no listing, a 503A pharmacy has no federal basis to compound it from bulk, and state boards cannot authorize what federal law does not. It is not an FDA approved drug and is not eligible for 503B outsourcing. It is a registered prescription drug in Russia. |
| WADA | WADA: WADA status unclear | WADA: WADA status unclear |
| Routes | Intranasal drops (Russian product and most sold forms), Subcutaneous injection (as sold, no published human data) | Intranasal drops (Russian product and most sold forms), Subcutaneous injection (as sold, no published human data) |
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient semax on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | No lawful compounded price: selank is off 503A Category 2 but is not on the 503A bulks list and was not among the peptides FDA presented to PCAC in July 2026. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Last verified |
Has Semax been tested directly against Selank?
No published trial has compared Semax and Selank directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do Semax and Selank cost?
| Dimension | Semax | Selank |
|---|---|---|
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient semax on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | No lawful compounded price: selank is off 503A Category 2 but is not on the 503A bulks list and was not among the peptides FDA presented to PCAC in July 2026. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Price detail | Semax price by channel | Selank price by channel |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Semax page and the Selank page.
Frequently asked questions
What is the difference between semax and selank?
Semax is built from a fragment of ACTH and was studied mainly for stroke recovery and cognition; selank is built from the immune peptide tuftsin and was studied mainly for anxiety. Both are intranasal Russian prescription peptides with the same stabilizing Pro-Gly-Pro tail. [1] [2] [6] [7]
Can semax and selank be used together?
No study has tested the combination, so any benefit or risk of using both is unknown. They are proposed to act on different systems, semax on BDNF and monoamines in rats and selank on GABA and enkephalin breakdown, which is the reasoning behind combined nasal products. Neither has FDA approval and neither is on the 503A bulks list, and HHS's draft policy covers only single-ingredient semax, so there is no lawful US source for a combined product. [5] [6] [7] [13]
Which is better for anxiety?
Selank is the one studied for anxiety: small Russian trials, two of them randomized but unblinded, reported anxiety relief similar to the benzodiazepine medazepam and earlier relief with fewer side effects when selank was added to phenazepam. None were placebo controlled or independently replicated, so the effect is not established by Western standards. [2] [3] [10]
Which is better for focus or memory?
Semax has the more relevant data, mostly stroke recovery studies and rat work showing increased hippocampal BDNF. No placebo controlled trial in healthy adults has tested either one for focus or memory. [1] [6] [9]
Can I get semax or selank from a US pharmacy?
Semax possibly, under conditions; selank, no. Neither is FDA approved or on the 503A bulks list. Semax is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (intranasal only) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Selank is not covered: its nomination was withdrawn and it was not reviewed. State law still applies. [4] [5] [13] [14]
Are semax and selank allowed in sport?
Neither is named on the WADA Prohibited List. Because both are non-approved substances, S0 could apply, so tested athletes should confirm with their anti-doping organization before use. [11]
Conditions studied
From the blog
- N-acetyl semax and selank amidate: is there any human data?
What N-terminal acetylation and C-terminal amidation are claimed to change in semax and selank, what the lab studies actually found, and why no human study has tested either modified version.
- Selank nasal spray: the evidence, and combining it with semax
What the intranasal selank studies measured, whether the route matters, and what is known about semax and selank nasal spray together: no trial has tested the combination.
- Selank withdrawal: dependence, benzodiazepines, and alcohol
Does selank cause withdrawal? What studies measured on dependence, how it compares with benzodiazepines, the rodent alcohol and opioid withdrawal studies, and the untested alcohol interaction.
- Semax nasal spray: what the intranasal studies show
Semax was developed in Russia as nasal drops. What the intranasal stroke and imaging studies measured, how nasal and injected data compare, and what the July 2026 PCAC meeting means.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Gusev EI et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova 1997PubMed 11517472, 1997
- [2]Zozulya AA et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova 2008PubMed 18454096, 2008
- [3]Medvedev VE et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova 2014PubMed 25176261, 2014
- [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [5]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [6]Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006PubMed 16996037, 2006
- [7]Vyunova TV et al. Peptide-based anxiolytics: the molecular aspects of heptapeptide selank biological activity. Protein Pept Lett 2018PubMed 30255741, 2018
- [8]Gusev EI et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova 2005PubMed 15792140, 2005
- [9]Gusev EI et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018PubMed 29798983, 2018
- [10]Medvedev VE et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova 2015PubMed 26356395, 2015
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). Semax vs Selank: evidence, cost, and legality. https://peptideagent.ai/compare/semax-vs-selank- HTML link
<a href="https://peptideagent.ai/compare/semax-vs-selank">Semax vs Selank: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.